Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
  • Challenge: Assessing cancer risk

Deep genomic and transcriptomic sequencing has allowed molecular classification of serous ovarian cancers using the “Oxford Classic”. This method enables accurate prediction of patient disease outcome by identifying EMT-high subtype tumours associated with a lower survival rate to focus appropriate treatment. This classification is being incorporated into a clinical trial of EMT-directed therapy. Advanced 3D cancer models have been developed for target discovery in minimal residual disease contexts. Oxford researchers have developed a novel whole genome sequencing method for accurate detection of mutations in minimal residual disease and in minute precursor lesions to track the events underlying tumour re-emergence and treatment response.